Ahmet Tüfekçi

Dr. Ahmet Tüfekçi

Department ofUrology, Sanko University, Gaziantep, Turkey (Türkiye)
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BTBeril Balci Topuz
Beril Balci Topuz
Ahmet TüfekçiAhmet Tüfekçi
Ahmet Tüfekçi
SCSibel Cangi
Sibel Cangi
OYOmer Aydin Yildirim
Omer Aydin Yildirim
MYMustafa Yıldırım
Mustafa Yıldırım
Background/Objectives: Systemic inflammation, nutritional status, and immune competence have emerged as important prognostic determinants in metastatic renal cell carcinoma (mRCC). The C-reactive protein–albumin–lymphocyte (CALLY) index integrates these parameters into a single composite biomarker, yet its utility in mRCC remains insufficiently explored. This study aimed to evaluate the prognostic significance of the CALLY index in mRCC and its associations with clinicopathological features and survival outcomes. Methods: A total of 68 patients with mRCC treated between 2017 and 2024 were retrospectively analyzed. All patients received first-line VEGF–TKI therapy, and 73.5% subsequently received second-line treatment, predominantly nivolumab. The CALLY index was calculated as (albumin × lymphocyte count)/(CRP × 104), and patients were stratified using the median cut-off (0.16). Survival outcomes were assessed with Kaplan–Meier and Cox regression analyses. Discriminative performance was evaluated using Harrell’s C-index and time-dependent ROC curves at 6, 12, and 24 months. Results: Low CALLY (≤0.16) was significantly associated with shorter PFS (4 vs. 8 months, p < 0.001) and OS (9 vs. 26 months, p < 0.001). In multivariate analysis, the CALLY index independently predicted both PFS (HR = 1.91, p = 0.045) and OS (HR = 2.89, p = 0.005). Time-dependent ROC analysis demonstrated increasing discriminative strength for PFS (AUC: 0.70 → 0.95) and modest decline for OS over time (AUC: 0.83 → 0.72). CALLY also showed strong associations with IMDC risk classification and peritoneal metastasis. Conclusions: The CALLY index is a simple, cost-effective, and objective prognostic biomarker that may independently predict progression and survival in mRCC. Its complementary value to the IMDC model supports its integration into routine risk stratification and real-world clinical decision-making.

1 January 2024 in Grand Journal of Urology
Verified
Journal Article
Closed access
BTBengisu Tüfekçi
Bengisu Tüfekçi
ESEmel Sönmezer
Emel Sönmezer
ÖBÖmer Bayrak
Ömer Bayrak
Ahmet TüfekçiAhmet Tüfekçi
Ahmet Tüfekçi

27 October 2026 in İstanbul Tıp Fakültesi Dergisi
Verified
Journal Article
Closed access
BTBeril Balci Topuz
Beril Balci Topuz
Ahmet TüfekçiAhmet Tüfekçi
Ahmet Tüfekçi
SCSibel Cangi
Sibel Cangi
ÖYÖmer Aydın Yıldırım
Ömer Aydın Yıldırım
MYMustafa Yıldırım
Mustafa Yıldırım
Objective: Immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) have transformed the treatment of metastatic renal cell carcinoma (mRCC), yet access limitations continue to shape real-world practice. This study evaluated the outcomes of second- and third-line systemic therapies administered after TKI failure within a single-center cohort.Materials and methods: This retrospective study included 50 patients with histologically confirmed mRCC treated between 2014 and 2024. Eligible patients had received at least one line of TKI therapy and subsequently received second-line nivolumab or axitinib. Survival outcomes were analyzed using Kaplan – Meier and log-rank tests.Results: The median age was 63 years; 76% were International Metastatic RCC Database Consortium intermediate-risk, and 82% had undergone nephrectomy. First-line therapy consisted of sunitinib (72%) or pazopanib (28%), with a median progression-free survival (PFS) of 7 months. In the second line, 40 patients (80%) received nivolumab and 10 (20%) axitinib. Median PFS and OS were 10 and 20 months for nivolumab vs. 4 and 5 months for axitinib (both p0.05). Five patients (four axitinib and one cabozantinib) were alive at the last follow-up.Conclusion: In this cohort, nivolumab was associated with longer PFS and OS compared to axitinib in the second-line setting after TKI failure, whereas axitinib and cabozantinib demonstrated similar outcomes in the third-line setting.

10 October 2026 in BMC Urology
Verified
Journal Article
Open access
PDF file
Ahmet TüfekçiAhmet Tüfekçi
Ahmet Tüfekçi
EKEyüp Kaplan
Eyüp Kaplan
ÖBÖzlem Başgut
Özlem Başgut
GDGörkem Durna
Görkem Durna
SSSüleyman Sağır
Süleyman Sağır
MEMehmet Sakıp Erturhan
Mehmet Sakıp Erturhan
Aggregate large language model (LLM) performance may obscure consequential errors and variability across repeated queries. We compared the clinical perform

18 April 2026 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Open access
PDF file
Bengisu TufekciBengisu Tufekci
Bengisu Tufekci
GUGünseli Usgu
Günseli Usgu
Ahmet TüfekçiAhmet Tüfekçi
Ahmet Tüfekçi
Background: Chronic hyperglycemia monitored by HbA1c may be associated with bladder dysfunction and lower urinary tract symptoms in women with diabetes mellitus, but the role of aerobic exercise in this process is unclear. Aims: The aim of our study is to investigate the impact of aerobic exercise (AE) on bladder function and urinary symptoms in women with Diabetes Mellitus (DM) who had Lower Urinary Tract Symptoms (LUTS). Methods: The study included 44 women randomly assigned to AE ( n = 22) and Control ( n = 22) groups. Both received behavioral therapy; the AE group additionally performed moderate-intensity aerobic exercise. Bladder function was assessed by urodynamics, blood glucose by HbA1c, voiding frequency by a 48-hour bladder diary, and urinary symptoms and quality of life by King’s Health Questionnaire (KHQ) and Bristol Female Lower Urinary Tract Symptoms (BFLUTS) questionnaire. Trial registration: ClinicalTrials.gov, NCT06249399. Results: The groups had similar characteristic urodynamic features before treatment ( p > 0.05). However after exercise training, improvements in favour of AE group regarding the following urodynamic parameters as voiding time ( p = 0.003), voided volume ( p = 0.008), first urge to urinate ( p = 0.003), compliance ( p < 0.001), maximum bladder capacity ( p = 0.021), subheadings of KHQ (general health ( p = 0.024), social limitation ( p = 0.013), mood ( p = 0.001), symptom severity) ( p = 0.042), and of BFLUTS (storage functions ( p = 0.004), quality of life ( p = 0.017), and total scores ( p = 0.012)), urinary frequency ( p = 0.003), and blood glucose levels ( p = 0.002). Conclusion: AE training for women with DM and LUTS, was associated with improved bladder function, urinary symptoms and urinary system related quality of life.

1 January 2026 in Central European Journal of Urology
Verified
Journal Article
Closed access
Ahmet TüfekçiAhmet Tüfekçi
Ahmet Tüfekçi
ISİlKer Seçkiner
İlKer Seçkiner
The Central European Journal of Urology is an open access quarterly-issued journal, which provides a forum for the presentation of original clinical, experimental and other research studies...